Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $15.1M
- Enterprise value
- $15.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.28
- 52-wk low
- $0.02
- Beta
- —
- Shares out
- 94.4M
5-year trend
What this company does
Adia Nutrition runs medical clinics that administer regenerative stem cell therapies, including umbilical cord stem cell treatments and autologous hematopoietic stem cell transplantation for orthopedic, pain, and autoimmune conditions. Revenue comes from clinical service fees at its Adia Med locations plus sales of its AdiaVita stem cell products through Adia Labs. The company exited shell status in mid-2024 after a custodianship-driven change of control and is now scaling a nationwide rollout of satellite stem cell clinics.
Generated from ADIA's filing dated 2026-03-31
Key risks
- Controlled company: Legends Investments Properties LLC (Larry Powalisz) holds Special Series A Preferred with 60% voting control, marginalizing common shareholders.
- Checkered corporate history: charter revoked 2013-2022, abandoned business, custodianship/receivership, multiple control changes; only exited shell status June 30, 2024.
- Regulatory risk on core product: UCB-SC therapies rely on FDA 361 HCT/P registration, an area facing active FDA enforcement against unapproved stem cell products.
Generated from ADIA's filing dated 2026-03-31
Profitability
Gross margin
27.4%
20.4%Operating margin
-52.3%
98.1%Net margin
-56.5%
98.0%Return on equity
153.5%
121.6%Return on assets
-66.5%
144.6%Leverage
Debt / equity
-3.31×
113.2%Long-term debt / equity
-2.33×
116.1%Debt / assets
143.3%
49.0%Earnings tracker
Not enough quarterly history for ADIA yet to draw an earnings tracker.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on ADIA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ADIA in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ADIA
No institutional holdings on file for ADIA yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
- 1
With no reported revenue and clinics only opened January 2025, what specific Q1-Q3 2025 revenue and patient volumes have Adia Med Winter Park actually generated?
- 2
Why was Biolete acquired then flipped to Cement Factory—where you hold only 18%—and what consideration and impairment did shareholders absorb?
- 3
How do you reconcile marketing UCB-SC therapies for orthopedic and anti-aging uses with FDA's 2024-2025 enforcement against 361 HCT/P claims?
Refreshed when ADIA files a new report · last from 2026-03-31